All News

November 21 2024

Dr. Joan Walker Pivots from NRG NCORP Leadership Role to Focus on Mentorship

Read more

November 12 2024

NRG Oncology Seeks Candidate for role of Imaging Committee Vice Chair

Read more

November 12 2024

Advocate Angle: "Life's a journey - travel well"

Written by Mark Harris, an NRG Oncology Patient Advocate Committee Member Read more

November 12 2024

Advocate Angle: Improving the Cancer Clinical Trial Matching Ecosystem

Written by Wenora Johnson, Patient/Research Advocate (Fight CRC) & NRG Oncology Patient Advocate Committee Member Read more

November 12 2024

FORTE Study Updates: November 2024

Read more

November 12 2024

NRG-GU011 (“NRG PROMETHEAN”): stereotactic radiotherapy with or without relugolix for PET-recurrent oligometastatic prostate cancer

Written by Bridget Koontz, MD FASTRO, AdventHealth Cancer Institute, National PI for NRG-GU011 Read more

November 12 2024

Moving anti-HER2 therapy into the peri-operative setting for locally advanced esophagogastric cancer

Written by Geoffrey Y. Ku, MD; Gastrointestinal Oncology Service, Dept of Medicine, Memorial Sloan Kettering Cancer Center Read more

November 12 2024

SBRT to the Primary Tumor Followed by Conventional Radiation Therapy and Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (NRG-LU008)

Read more

November 12 2024

PSC Column: Optional Specimen Collection

Read more

October 11 2024

NRG Oncology seeks to fill the position of Vice-Chair, NRG Oncology NCORP Cancer Care Delivery Research Committee

Read more

October 10 2024

FORTE Study Updates: October 2024

Read more

October 10 2024

PSC Column: Understanding Consent Withdrawal: Guidelines for Patient Participation and Data Management

Read more

October 10 2024

Advocate Angle: An Interview with Laurel Pracht: Making Strides to Fund the Future in Ovarian Cancer Research

Our NRG Communications team interviewed Laurel to discuss the fundraising efforts and her passions surrounding cancer research and health equities. Read more

October 10 2024

Navigating the Vast World of Clinical Research Following an Adolescent Young Adult (AYA) Cancer Diagnosis

Advocate Angle by Jade Gibson an NRG Oncology Patient Advocate Read more

September 30 2024

NRG Oncology Trial Implies the Addition of Atezolizumab Concurrently to Standard of Care Does Not Improve Survival in Limited-Stage Small Cell Lung Cancer

Read more

September 30 2024

NRG Oncology Trial Supports Radiotherapy and Cisplatin Should Remain the Standard of Care for p16+ Oropharyngeal Cancer

Read more

September 18 2024

Cancer Cooperative Group leaders propose a re-engineering of the nation’s correlative science program for cancer

Read more

September 16 2024

Quality-of-Life Outcomes Reported from NRG Oncology Trial Studying Whole-Breast Irradiation vs Accelerated Partial-Breast Irradiation after Breast-Conserving Surgery

Read more

September 12 2024

FORTE Study Updates: September 2024

Read more

September 12 2024

NCORP Pilot Project Awardees

Read more

September 12 2024

PI Interview: The COMMIT Study of Immunotherapy for dMMR Metastatic Colorectal Cancer (NRG-GI004/SWOG S1610)

Read more

September 12 2024

Adding Stereotactic Radiation Therapy to Immune Therapy for Patients with Advanced Renal Cell Cancer (NRG-GU012, The “SAMURAI” Study)

NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) Read more

September 12 2024

Comparing Stereotactic Radiosurgery to Fractionated Stereotactic Radiosurgery for Patients with Cancer that has Spread to the Brain (NRG-BN013)

NRG-BN013: Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases Read more

September 12 2024

PSC Column: Cancer: DTL Overview

Read more

September 12 2024

My Hereditary Cancer Journey: Looking Back, Look Forward

Article by Diane Rose an NRG Oncology Patient Advocate Read more

September 11 2024

NRG Oncology Annual Call for Committee Membership Applications

Read more

September 06 2024

NRG Oncology Study Results Indicate that Radiation and Chemotherapy After Surgery Could be a Viable Alternative to Radical Cystectomy for Patients with Recurrent Bladder Cancer

Read more

August 12 2024

FORTE Study Updates: August 2024

Read more

August 12 2024

NRG Oncology PSC 2024 Summer Meeting Wrap Up

Read more

August 12 2024

NRG Oncology Awards 10 Fellows for the Early Career & New Investigator Mentored Fellowship Program

Read more

August 12 2024

Lessons Learned with Laurie’s Journey

Read more

August 06 2024

NRG Oncology Seeks Candidates for Theranostics Subcommittee Chair and Vice Chair

Read more

July 11 2024

Mei-Yin Polley, PhD, Promoted to Full Professor at the University of Chicago

Read more

July 11 2024

FORTE Study Updates: July 2024 Newsletter

Read more

July 11 2024

NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial

Read more

July 11 2024

PSC Column: Cancer: No One is Immune

Read more

July 11 2024

NRG’s Data Monitoring Committee: Through the Lens of an Advocate

Read more

June 13 2024

PSC at the NRG 2024 Summer Meeting

Read more

June 13 2024

FORTE Study Updates: June 2024 Newsletter

Read more

June 13 2024

NRG-CC012CD Opens to Accrual: Addressing Patient Symptom Monitoring and Management

Read more

June 13 2024

Advancing Research: NRG Advocates Call to Action for Uterine Cancer Awareness Month and National Cancer Survivors Month

Read more

June 13 2024

NRG Oncology Publication Demonstrates Radiotherapy Should Remain Standard of Care, Future Research Should Consider Tumor Subsets

Read more

June 04 2024

NRG Oncology Abstract Considered “Best of ASCO” for 2024 Shows Difference in Outcomes for Node-Negative Versus Node-Positive Pancreatic Cancer Patients when Adding Chemoradiation to Systemic Therapy

Read more

May 28 2024

NRG Oncology Appoints New Vice-Chairs for their Patient Advocate Committee

Read more

May 22 2024

NSABP Foundation / NRG Oncology Biospecimen Bank (PGH) relocates to Nova Place Campus

Read more

May 16 2024

NRG Oncology Announces New Leadership of Three Committees

Read more

May 14 2024

FORTE Update for May 2024 Newsletter

Read more

May 14 2024

NRG Well-positions Affiliated Scholars to Compete for the Most Elite Federal Funding Opportunities!

Read more

May 14 2024

Patient Reported Outcomes – Compliance Improvement

Read more

May 14 2024

Guidance on the Re-consenting Process

Read more

May 14 2024

Leveraging Veteran Data for the Benefit of Veteran Cancer Patients

Read more

May 14 2024

Summary of Research Results for NRG Oncology Study Participants

Read more

May 14 2024

NRG Oncology seeks to fill the position of Vice-Chair, NRG Oncology Early Phase Trial Oversight Committee

Read more

April 10 2024

Danielle Enserro, PhD Appointed the Associate Director of Biostatistics and Statistical Programming

Read more

April 10 2024

FORTE Updates - April 2024

Read more

April 10 2024

Lost in the Shuffle: Navigating Patient Follow-up in Clinical Trials

Read more

April 10 2024

Trial in Development Feature: NRG-HN014

Read more

April 10 2024

Trial in Development Feature: NRG-HN012

Read more

April 03 2024

NRG Oncology Announces New Leadership of Cancer Prevention & Control Committee

Read more

March 25 2024

NRG Oncology is seeking an experienced Patient Advocate to serve as Vice Chair for its Patient Advocate Committee.

Read more

March 14 2024

Hypofractioned Post-Prostatectomy Radiotherapy New Acceptable Practice Standard Based on NRG Oncology Trial Findings

Read more

March 14 2024

NRG Oncology seeks to fill the position of Chair, NRG Oncology Genitourinary Cancer Committee

Read more

March 12 2024

NRG Oncology seeks to fill the position of Chair, NRG Oncology Developmental Therapeutics Gynecologic Phase I Subcommittee

Read more

March 12 2024

RFAs for the NRG Early Career & New Investigators (ECNI) Committee AND for the NRG ECNI Mentored Fellowship

Read more

March 12 2024

NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Read more

March 12 2024

NRG-CC005 / FORTE at #NRG2024

Read more

March 12 2024

Trials in Progress Update: The Janus Rectal Cancer Trial (Alliance A022104/NRG-GI010)

Read more

March 12 2024

Trials in Progress Update: CIRCULATE-NORTH AMERICA (NRG-GI008)

Read more

March 12 2024

Trials in Progress Update: The COMMIT Study (NRG-GI004/SWOG S1610)

Read more

March 12 2024

Protocol Support Committee - NRG 2024 Winter Meeting Wrap Up

Read more

February 27 2024

NRG Oncology Announces New Leadership of Canadian Members Subcommittee

Read more

February 22 2024

Seeking Applications for BIQSFP Funding for Non-real Time Integrated Studies for NCTN & NCORP Trials

Read more

February 12 2024

NRG Oncology seeks to fill the position of Chair, NRG Oncology NCORP Cancer Prevention Committee

Read more

February 12 2024

Legacy of Dr. Edith Mitchell

Read more

February 12 2024

Protocol Support Committee Column: Addressing Diversity in Clinical Trials

Read more

February 12 2024

Trial Adding Relatlimab to Immunotherapy for Recurrent or Metastatic Nasopharyngeal Cancer Activates (NRG-HN011)

Read more

February 12 2024

NRG Activates Phase II Study for AR-Positive Ovarian Granulosa Cell Tumors (NRG-GY033)

Read more

February 12 2024

FORTE: National Cancer Prevention Month 2024

Read more

February 12 2024

PI Interview: The NRG-CC010 Study for SLN Mapping on Patient-Reported Lower Extremity Limb Dysfunction in Endometrial Cancer

Read more

February 12 2024

PI Interview: The NRG-CC008 (SOROCk) Study Comparing Two Surgical Procedures for Women with BRCA1 Mutations to Assess Risk Reduction for Ovarian Cancer

Read more

February 06 2024

NRG Oncology and the University of Pittsburgh demonstrate that a Machine Learning Model Predicts Oxaliplatin Benefit Using Data from Two NSABP Clinical Trials

Read more

February 02 2024

NRG Oncology Selects Health Equity Fellows for 2024

Read more

January 26 2024

Accepting Applications for Vice Chair, NRG Radiation Oncology Committee

Read more

January 17 2024

A Message from the Chairs of NRG Oncology’s Research Strategy Committee

2023: The Year in Review Read more

January 17 2024

The FORTE Workshop is coming soon…

Read more

January 17 2024

PSC Continuing Education Sessions at #NRG2024

Read more

January 17 2024

Cervical Cancer Awareness Month

2023 Cervical Highlights Read more

January 17 2024

Annual Message from the NRG Oncology Group Chairs

Read more

December 15 2023

NRG Oncology seeks to fill the position of Chair, NRG Oncology Canadian Members Subcommittee

Read more

December 11 2023

Managing Data and Query Expectation in NCI Research Studies

Read more

December 11 2023

The “High Five Trial” for High-Risk Prostate Cancer Activates (NRG-GU013)

Read more

December 11 2023

NRG PCOR Educational Session at #NRG2024 in Orlando

Read more

December 11 2023

Honoring a Legacy: Dr. Worta McCaskill-Stevens

Read more

December 05 2023

NRG-BR008, HERO Study Seeks to Optimize use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer

Read more

November 14 2023

ADVERSE EVENT REPORTING: One site’s use of EMR functionality to establish Best Practice

Read more

November 14 2023

FORTE Study Update - November 2023

Read more

November 14 2023

Pancreatic Cancer Awareness Month

Updates from the NRG Oncology Pancreatic Cancer Working Group Read more

November 14 2023

National Family Caregivers Month

The Caregiver Experience with Clinical Trials: Understanding the Emotions and Clarifying the Details for Patients Read more

November 09 2023

FORTE, a Colorectal Cancer Prevention Clinical Trial, accrues its first 1,000 participants

Read more

October 24 2023

New Vice Chair named for NRG Health Disparities Committee (HDC)

Dr. Evan Graboyes named HDC Vice Chair, effective immediately Read more

October 17 2023

FORTE Study Update - October 2023

Read more

October 17 2023

Informed Consent Guidance Now Available

Read more

October 17 2023

Megan Mullins, PhD, NRG Cancer Care Delivery Researcher, Examines Health Equity Issues in Latest Publication

Read more

October 17 2023

NRG-BR009 (“OFSET”): A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression and Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score of ≤ 25

Read more

October 03 2023

RTOG 1308 Accrual Completion: First Phase III NCTN Clinical Trial Comparing Photon Versus Proton Therapy to Meet Accrual Target

Read more

September 14 2023

FORTE Study Update - September 2023

Read more

September 14 2023

Pharmaceutical Management Branch (PMB) AURORA Updates

Read more

September 14 2023

Reminder to review CTEP IAM account and NRG roster status

Read more

September 12 2023

Secondary Analysis of NRG Oncology-RTOG 0617 Presented at IASLC 2023

Read more

August 14 2023

NRG Oncology PSC 2023 Summer Meeting Wrap Up

Read more

August 14 2023

FORTE Study Update - August 2023

Read more

July 21 2023

NRG Oncology Honors Dr. Walter ‘Wally’ Curran as First NRG Oncology Gold Medalist

Read more

July 21 2023

NRG Oncology Announces New Leadership of the Organization’s Cancer Prevention & Control Committee, Immunotherapy Subcommittee, and Publications Committee

Read more

July 17 2023

FORTE Study Update - July 2023

Read more

July 17 2023

Life as an Adolescent Young Adult Cancer Survivor

Read more

July 06 2023

NRG Oncology seeks to fill the position of Vice-Chair, NRG Oncology NCORP Health Disparities Research Committee

Read more

June 15 2023

Addition of EBRT to Brachytherapy Did Not Improve Outcomes for Men with Intermediate-Risk Prostate Cancer, Brachytherapy Alone Remains Standard of Care

Read more

June 09 2023

PSC at the NRG 2023 Summer Meeting

Read more

June 09 2023

FORTE Study Update: June 2023

Read more

June 09 2023

NRG Oncology Awards 11 Fellows for the Early Career & New Investigator Mentored Fellowship Program

Read more

June 09 2023

Comparing Stereotactic Radiosurgery to Hippocampal-Avoidant Whole Brain Radiotherapy for Patients with High Brain Metastasis Velocity at Distant Brain Relapse Following Stereotactic Radiosurgery (NRG-BN009)

Read more

June 09 2023

SBRT to the Primary Tumor Followed by Conventional Radiation Therapy and Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (NRG-LU008)

Read more

June 09 2023

Breaking Impossible

Read more

June 01 2023

Through a joint project and on common ground, a large number of investigators from US trial groups and the National Cancer Institute reached consensus on issues regarding the strength of pre-clinical data and study designs via extensive interactions

Read more

May 10 2023

Introducing SDMC Statistics Division Member, Eric Polley, Ph.D.

Read more

May 10 2023

Spotlight on the PSC Working Groups

Read more

May 10 2023

FORTE Study Update: May 2023

Read more

May 10 2023

Not Leaving Veterans Behind

Read more

May 10 2023

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer (NRG-CC009)

Read more

May 10 2023

Should SRS be Delivered Before or After Surgery for Patients with Brain Metastases? (NRG-BN012)

Read more

April 28 2023

NRG Oncology Seeks to Fill the Position of Vice-Chair, NRG Oncology NCORP Cancer Control Committee

Read more

April 27 2023

Patient-Reported Outcomes from an NRG Oncology Study of Androgen Deprivation Therapy with Dose-Escalated Radiotherapy for Intermediate-Risk Prostate Cancer Show No Clinically Meaningful Differences in Scores at One Year Post-Treatment

Read more

April 27 2023

NRG Oncology Trial Does Not Improve Overall Survival, but Shows Improvements in Several Clinical Outcomes for Men with Intermediate-Risk Prostate Cancer

Read more

April 27 2023

NRG Oncology Study Results Confirm Conventional External Beam Radiotherapy Should Remain Standard of Care in Treating Localized Vertebral Metastases of the Spine

Read more

April 18 2023

Webinar: NRG-GI004 / SWOG S1610 COMMIT Study Amendment 9 Overview

Read more

April 12 2023

Show Me the Money

Read more

April 12 2023

FORTE at #NRG2023!

Read more

April 12 2023

Comparing Selumetinib and Olaparib to Selumetinib Alone for Ovarian and Endometrial Cancers with RAS Pathway Mutations (EAY191-N4, A ComboMATCH Treatment Trial)

Read more

April 12 2023

Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone-Receptor Positive Metastatic Breast Cancer (EAY191-N2, A ComboMATCH Treatment Trial)

Read more

April 12 2023

WVOCA Donates Additional Funds to the NRG Oncology Health Equity Fellowship Program

Read more

April 12 2023

PI Perspective: The Journey of NRG-GY018

Read more

April 12 2023

NRG Oncology and RTOG Foundation Integrated Efforts in the Head and Neck Cancer Committee

Read more

April 12 2023

Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-positive Salivary Gland Cancer (NRG-HN010)

Read more

April 06 2023

Webinar: Surgical Implications of ctDNA: Is this the future for colon cancer?

Read more

March 31 2023

NRG Oncology Combined Trial Long-Term Results Indicate that Pathologic Complete Response is Prognostic of Outcomes for Soft Tissue Sarcoma Patients

Read more

March 27 2023

Late-Breaking Results of NRG-GY018 Presented at SGO 2023: Study Demonstrates Improved PFS Outcomes with the Addition of Pembrolizumab to Chemotherapy for Women with Advanced or Recurrent Endometrial Cancer

Read more

March 26 2023

Study Identifies Two Promising Molecular Targets for Drug Development in Recurrent and Metastatic Cervical Cancer

Read more

March 25 2023

The Utilization of Atezolizumab as a Primer for Chemoradiation Results in Promising Immune System Alterations for Women with Locally Advanced Cervical Cancer

Read more

March 25 2023

The Addition of Gemcitabine with Cisplatin and Intensity-Modulated Radiation Therapy Improves Outcomes for Women with Locally Advanced Vulvar Cancer

Read more

March 15 2023

Circulating Tumor DNA: One of Our Newest Tools for Managing Solid Tumors

Read more

March 15 2023

NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer

Read more

March 15 2023

FORTE Study News: It’s Colorectal Cancer Awareness Month!

Read more

March 09 2023

RFAs for the NRG Early Career & New Investigators (ECNI) Committee AND for the NRG ECNI Mentored Fellowship

Read more

February 16 2023

NRG NCORP Solicits PILOT Projects for NRG NCORP Health Disparities Research (HDR) Priorities

Read more

February 15 2023

NRG Oncology seeks to fill the position of Chair of the NRG Oncology Publications Committee

Read more

February 15 2023

NRG Oncology seeks to fill the position of Vice-Chair, NRG Oncology Immunotherapy Subcommittee

Read more

February 15 2023

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Prevention Control (CPC) Priorities

Read more

February 15 2023

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Care Delivery Research (CCDR) Priorities

Read more

February 14 2023

Protocol Support Committee (PSC) Column: NRG Oncology PSC 2023 Winter Meeting Wrap Up

Read more

February 14 2023

Initial Report on Establishing Working Groups within the Head and Neck Cancer Committee

Read more

February 14 2023

FORTE Study Update: Participant Travel Allowance

Read more

February 09 2023

NRG Oncology Selects Three Awardees for Health Equity Fellowship Program

Read more

February 03 2023

NRG Oncology NRG-GY018 Study Demonstrates Significantly Improved Progression Free Survival Outcomes for Women with Advanced or Recurrent Endometrial Cancer with the Addition of Pembrolizumab to Chemotherapy

Read more

January 18 2023

Set Up for Success - Coordinating RECIST 1.1: A Community Hospital Perspective

Read more

January 18 2023

#FORTEStudy Workshop

Read more

January 18 2023

NRG Innovations Continue in Cancer Care Delivery Research

Read more

January 18 2023

Adding Atezolizumab to Cisplatin and Radiotherapy for Node-Positive Locally Advanced Cervical Cancer (NRG-GY017)

Read more

January 18 2023

A Message from the NRG Oncology Research Strategy Committee Chairs: 2022: The Year in Review

Read more

January 18 2023

A Message from the NRG Oncology Group Chairs: 2022 in Review and a Look Ahead

Read more

December 19 2022

NRG Oncology Holiday Closures for 2022

Read more

December 12 2022

NRG Meeting PSC Information

Read more

December 12 2022

NRG-CC005/FORTE Site Implementation Guide: Part 1

Read more

December 12 2022

Julian Hong, M.D., M.S.: Steward of Cancer Care Delivery Research and Innovation

Read more

December 12 2022

NRG Oncology Announces Leadership of New Diversity, Equity, and Inclusion Committee, New Vice Chair for Ancillary Projects Committee

Read more

November 09 2022

Protocol Support Committee Column: NRG Best Practice Tool

Read more

November 09 2022

Dr. Jong H. Jeong Joins NRG Oncology SDMC

Read more

November 09 2022

#FORTEStudy is on YouTube!

Read more

November 09 2022

Assessing SBRT to the Primary Tumor Followed by Conventional Radiation Therapy with Concurrent Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (NRG-LU008)

Read more

November 09 2022

Assessing the Addition of IMPRINT to Surgery and Systemic Therapy for Malignant Pleural Mesothelioma (NRG-LU006)

Read more

November 03 2022

NRG Oncology Patient Advocate Committee - Call for Candidates

Read more

October 24 2022

Multi-Modal Artificial Intelligence Models Offer a More Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer than Current NCCN Standard

Read more

October 24 2022

NRG Oncology Trial NRG-HN004 Shows Addition of Durvalumab to Radiation Does Not Improve Outcomes over Cetuximab for Head & Neck Squamous Cell Carcinoma Patients with a Contraindication to Cisplatin, Highlights Need for Further Research

Read more

October 24 2022

Three Week Hypo-fractionated Whole Breast Irradiation (WBI) with Concurrent Boost is not Inferior to Conventional WBI with a Sequential Boost Following Lumpectomy for Patients with High-Risk, Early-Stage Breast Cancer

Read more

October 24 2022

The Addition of Stereotactic Body Radiation Therapy (SBRT) to Sorafenib in Patients with Advanced Hepatocellular Carcinoma Improves Overall Survival

Read more

October 12 2022

The Protocol Support Committee (PSC) Wants You!

Read more

October 12 2022

#FORTEStudy in Chicago!

Read more

October 12 2022

Comparing Docetaxel and Trastuzumab to Ado-Trastuzumab Emtansine for HER2-positive Salivary Gland Cancer (NRG-HN010)

Read more

October 12 2022

Assessing the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer (NRG-CC010)

Read more

October 12 2022

NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer

Read more

October 12 2022

NRG-BR007 (“DEBRA”): A Phase III Clinical Trial Evaluating the De-escalation of Breast Radiation for a More Conservative Treatment of Patients With Low-Risk, Hormone-Sensitive, Node-Negative Breast Cancer

Read more

October 06 2022

NRG Oncology Appoints Chair & Vice Chair of Radiation Oncology Committee

Read more

September 26 2022

Foundation Accrual Credit for NRG Membership Requirements Announcement

Read more

September 21 2022

Intensity Modulated Radiotherapy Improved Patient-Reported Outcomes on NRG Oncology Clinical Trial

Read more

September 15 2022

In Memoriam: James Lloyd Hoehn, MD, FACS

Read more

September 15 2022

Protocol Committee Support (PSC) Column: No Surprises Billing Act 2022

Read more

September 15 2022

NRG Health Equity Fellowship Call for Applications

Read more

September 15 2022

Comparing the Addition of Radiation before or After Surgery for Patients with Brain Metastases (NRG-BN012)

Read more

September 15 2022

Comparing Every Three Week Versus Weekly Cisplatin with Radiotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (NRG-HN009)

Read more

September 15 2022

NRG-GU011 (“NRG PROMETHEAN”) study of SABR with or without relugolix for PET-recurrent oligometastatic prostate cancer

Read more

September 15 2022

NRG-GU009 ( “PREDICT-RT”) Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation

Read more

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.